for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amicus Therapeutics, Inc.

FOLD.O

Latest Trade

14.79USD

Change

-0.14(-0.94%)

Volume

970,318

Today's Range

14.54

 - 

14.99

52 Week Range

6.25

 - 

16.13

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing

Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS SECURES $400 MILLION NON-DILUTIVE DEBT FINANCING.AMICUS THERAPEUTICS INC - REITERATES 2020 GALAFOLD REVENUE OF $250-$260M AND 2020 OPERATING EXPENSE GUIDANCE.AMICUS THERAPEUTICS INC - EXECUTED A DEFINITIVE AGREEMENT FOR A $400 MILLION CREDIT FACILITY WITH HAYFIN CAPITAL MANAGEMENT.AMICUS THERAPEUTICS INC - NEW LOAN IS EXPECTED TO BE FUNDED PRIOR TO AUGUST 4, 2020.AMICUS THERAPEUTICS INC - PROCEEDS WILL BE USED TO REFINANCE EXISTING DEBT, OTHER GENERAL PURPOSES.AMICUS THERAPEUTICS INC - FULLY ON TRACK THIS YEAR TO ACHIEVE GALAFOLD REVENUE BETWEEN $250 MILLION TO $260 MILLION.

Amicus Therapeutics Announces First Quarter 2020 Financial Results

May 7 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATES.Q1 LOSS PER SHARE $0.35.SEES FY 2020 REVENUE $250 MILLION TO $260 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.28 -- REFINITIV IBES DATA.AMICUS THERAPEUTICS - TOTAL REVENUE IN Q1 2020 WAS $60.5 MILLION, A YEAR-OVER-YEAR INCREASE OF 78%.SEES NON-GAAP OPERATING EXPENSE GUIDANCE FOR FULL-YEAR 2020 $410 MILLION TO $420 MILLION.Q1 REVENUE VIEW $57.5 MILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $257.1 MILLION -- REFINITIV IBES DATA.

Amicus Therapeutics Sees FY 2020 Revenue Of $250 Mln To $260 Mln

March 2 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES FULL-YEAR 2019 FINANCIAL RESULTS AND 2020 CORPORATE UPDATES.SEES FY 2020 REVENUE $250 MILLION TO $260 MILLION.REITERATED ITS FULL-YEAR 2020 GUIDANCE.STRONG BALANCE SHEET WITH $450 MILLION+ CASH - CASH RUNWAY WELL INTO 2022.

Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook And Financial Guidance

Jan 13 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2020 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS INC- SEES FULL-YEAR 2020 TOTAL GALAFOLD REVENUE OF $250 MILLION TO $260 MILLION BASED ON AVERAGE EXCHANGE RATES FOR 2019.

Amicus Therapeutics Reports Q3 Loss Per Share Of $0.24

Nov 11 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q3 LOSS PER SHARE $0.24.SEES FY 2019 REVENUE $170 MILLION TO $180 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $177.3 MILLION -- REFINITIV IBES DATA.REITERATED FY 2019 GUIDANCE.QTRLY GLOBAL REVENUE FOR FABRY PRECISION MEDICINE GALAFOLD $48.8 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $514.2 MILLION AT SEPTEMBER 30.EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.NOW EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.EXTENDED CASH RUNWAY PROJECTION FROM 2021 TO WELL INTO FIRST HALF OF 2022.Q3 REVENUE VIEW $47.7 MILLION -- REFINITIV IBES DATA.

Amicus Announces Additional Positive Interim Clinical Data For Cln6 Batten Disease Gene Therapy

Oct 24 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS ANNOUNCES ADDITIONAL POSITIVE INTERIM CLINICAL DATA FOR CLN6 BATTEN DISEASE GENE THERAPY AT 48TH ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY.AMICUS THERAPEUTICS INC - EVIDENCE OF DISEASE STABILIZATION IN 7 OF 8 CHILDREN WITH DATA FOR UP TO 2 YEARS POST-TREATMENT.AMICUS THERAPEUTICS INC - NEW DATA SUPPORT MEANINGFUL IMPACT ON MOTOR AND LANGUAGE FUNCTION IN CHILDREN WITH FATAL NEUROLOGIC DISEASE.

Amicus Therapeutics Says Co Raises Lower End Of FY19 Global Galafold Revenue Guidance To $170 Mln-$180 Mln

Oct 10 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES PRELIMINARY THIRD QUARTER 2019 REVENUE AND FINANCIAL OUTLOOK AT 2019 ANALYST DAY.AMICUS THERAPEUTICS INC - COMPANY RAISES LOWER END OF FY19 GLOBAL GALAFOLD REVENUE GUIDANCE TO $170 MILLION -$180 MILLION.AMICUS THERAPEUTICS INC - CASH RUNWAY EXTENDED FROM 2021 TO WELL INTO 1H 2022.AMICUS THERAPEUTICS INC - EXPECTS TO RECORD APPROXIMATELY $48 MILLION (PRELIMINARY AND UNAUDITED) IN GALAFOLD REVENUE FOR Q3 2019.AMICUS THERAPEUTICS INC - AMICUS NOW EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.

Amicus Therapeutics Q2 Loss Per Share $0.36

Aug 8 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.Q2 REVENUE $44.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $41.1 MILLION.REITERATING FY19 REVENUE GUIDANCE OF $160M-$180M.

Amicus Therapeutics, Catalent Biologics Enter Strategic Partnership For Gene Therapy Development And Manufacturing

July 2 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS AND CATALENT BIOLOGICS ENTER STRATEGIC PARTNERSHIP FOR GENE THERAPY DEVELOPMENT AND MANUFACTURING.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING AGREEMENT WITH PARAGON GENE THERAPY, A UNIT OF CATALENT BIOLOGICS.AMICUS THERAPEUTICS INC - COLLABORATION INCLUDES MULTIPLE ACTIVE PRECLINICAL LYSOSOMAL DISORDER PROGRAMS.

Amicus Therapeutics And Brammer Bio Enter Gene Therapy Collaboration

July 1 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS AND BRAMMER BIO, A PART OF THERMO FISHER SCIENTIFIC, ENTER STRATEGIC GENE THERAPY DEVELOPMENT AND MANUFACTURING COLLABORATION.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING COLLABORATION WITH THERMO FISHER SCIENTIFIC.AMICUS THERAPEUTICS - THERMO FISHER, CO TO DEVELOP PLATFORM MANUFACTURING CAPABILITIES TO SUPPORT BROADER PORTFOLIO OF AAV GENE THERAPY PROGRAMS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up